PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
about
Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseasesDual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysisComparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.Approaching 'Kit-Type' Labelling with (68)Ga: The DATA Chelators.The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y.Evolution of bombesin conjugates for targeted PET imaging of tumors.Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CTPreparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelatorPositron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.New lyophilized kit for rapid radiofluorination of peptidesSynthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant armsPeptide receptor targeting in cancer: the somatostatin paradigm.New Bifunctional Chelator p-SCN-PhPr-NE3TA for Copper-64: Synthesis, Peptidomimetic Conjugation, Radiolabeling, and Evaluation for PET Imaging.Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor.H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.Promising bifunctional chelators for copper 64-PET imaging: practical (64)Cu radiolabeling and high in vitro and in vivo complex stability.Prospective of ⁶⁸Ga-radiopharmaceutical development.Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis.Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.Feasibility and availability of ⁶⁸Ga-labelled peptides.Radiopharmaceutical development of radiolabelled peptides.The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging.Matching chelators to radiometals for radiopharmaceuticals.Endogenous compounds labeled with radionuclides of short half-life-some perspectives.Chelators for copper radionuclides in positron emission tomography radiopharmaceuticalsMANOTA: a promising bifunctional chelating agent for copper-64 immunoPET.⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.Current advances in ligand design for inorganic positron emission tomography tracers (68)Ga, (64)Cu, (89)Zr and (44)Sc.Molecular imaging probes derived from natural peptides.A Modular Dual Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting.PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity.Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.Nanogels from metal-chelating crosslinkers as versatile platforms applied to copper-64 PET imaging of tumors and metastasesPET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate.Radiolabeled peptides: valuable tools for the detection and treatment of cancerNeodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing VectorSomatostatin analogues labeled with copper radioisotopes: current status.
P2860
Q27025187-A9453695-151C-49F6-8E38-89D926E54A85Q27027682-5725E8DC-B69E-4208-BBE4-D30FBAEC8036Q27339846-F48DBC9B-40A6-4D7D-B814-3833F7909B7DQ30938260-595D67D7-61B2-4299-AE5F-7A16E5883BCCQ33851546-B665A518-6601-4585-81DB-CB2B79C88700Q34424982-34F44E5B-66BD-4268-B099-7B9C51E93DF8Q34503869-382A01ED-488E-40AC-9FE0-D2767941CE2DQ34677178-063E1BA6-2ABB-4B4C-BC6D-6D24CCB8F4EFQ34696158-B401D9B4-79D3-4B87-A59C-95D0CE16FD4EQ35846622-DFAECF12-957E-4919-A0C5-73E801A59A5BQ36291655-770662DE-3001-4CD6-A141-3173941F280FQ36638046-97E137AC-978F-4ABB-B1DD-F29FD80AEC88Q37104310-AE01678A-2A2E-4470-B0B3-EF2B7CC29F33Q37273212-725E8F10-62AC-416C-9105-0E850A1F4939Q37412579-4CAF2E8F-9389-420A-B959-6EF317E29752Q37424123-DE502BD0-0F60-4CF6-AEFD-142DB91C9EC4Q37435222-F804BEA2-363C-494C-B099-92D33D760A91Q37515861-53E00515-32C2-476C-BE5A-43C362913987Q37623394-6469F80D-D674-4C09-ABA8-4E0BF4C55208Q37724107-CE04C438-8F22-4CBA-A952-435F91C2EF81Q37731335-D5F460F0-0B05-4BB1-9D02-B774655ED8F1Q37990396-C0AF4B68-1466-4C02-9F6A-AAC9C74E987CQ37990399-BE33EF35-E9B7-4B85-8EC1-B1954B6E9415Q38080002-0E264F10-6C62-4E8D-92AA-D90310108EB8Q38156660-E05A4384-742D-43A2-B9B2-80DE69AD2E7FQ38166981-6D333D4A-ECF9-46A4-B201-29A4D7AE34DDQ38172069-49E3DFDA-530B-483A-95C8-6E331205D80EQ38693617-74213161-E8A7-4EEE-A3B4-880209342609Q38705627-510B9D07-1359-40EE-A3DB-DF6E8CD4E7F2Q38729041-41E238CC-4F5E-48C2-9084-C445BE5DA09BQ38748846-1572108F-CA9A-4175-B01A-2D0499028DEAQ38749965-C1E4322A-C688-43F7-851F-AE62D7864956Q38846349-4BE2EA42-DB5F-4371-9239-3DB4D3B6AD51Q38876206-D726C7F1-4E59-40F6-9D96-DF51718DA1D2Q39016753-31477DF5-6D3F-4695-8FC2-51F54A360788Q39065411-F7B6F40B-6DCE-4B15-858D-6C95459FD098Q39066068-6E65CFD8-7F61-41EB-834B-E523A40209B5Q39596344-BEF0A001-8506-4480-B274-D941A57BAF25Q40986557-20930371-B5A8-4AC1-8C1D-64558332839EQ42133416-FF70136B-3AF8-44AD-911C-22663DB1CB75
P2860
PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
PET of somatostatin receptor-p ...... chelate makes the difference.
@en
PET of somatostatin receptor-p ...... chelate makes the difference.
@nl
type
label
PET of somatostatin receptor-p ...... chelate makes the difference.
@en
PET of somatostatin receptor-p ...... chelate makes the difference.
@nl
prefLabel
PET of somatostatin receptor-p ...... chelate makes the difference.
@en
PET of somatostatin receptor-p ...... chelate makes the difference.
@nl
P2093
P1476
PET of somatostatin receptor-p ...... chelate makes the difference.
@en
P2093
Beatrice Waser
Helmut R Maecke
Keelara Abiraj
Luigi Del Pozzo
Maria Luisa Tamma
Melpomeni Fani
Renzo Cescato
Rosalba Mansi
Wolfgang A Weber
P304
P356
10.2967/JNUMED.111.087999
P407
P577
2011-06-16T00:00:00Z